the product in the database has an inactive status
indications:
Active immunization against infections caused by the hepatitis A virus. Vaccination is recommended in healthy people exposed to infection or transmission of infections and in whom the development of hepatitis A, due to other diseases, may be a life-threatening factor (eg people infected with HIV and people diagnosed with hepatitis C). The vaccine does not protect against viral hepatitis caused by other types of virus than Type A.
Composition:
1 dose of vaccine (0.5 ml or 1 ml) contains 25 U or 50 U of inactivated hepatitis A virus.
Action:
Hepatitis A vaccine. Contains inactivated viruses derived from the strain resulting from multiple passage of the attenuated, tested starting strain. Viruses are propagated, purified, formaldehyde inactivated and adsorbed on amorphous aluminum hydroxyphosphate sulfate. The vaccine does not give rise to immunity against hepatitis A immediately after vaccination - the level of antibodies can be determined after 2-4 weeks. In clinical trials a high rate of seroconversion was obtained: in children and adolescents - 97%, in adults - 95% in 4 weeks. after the initial dose. The persistence of immunological memory was confirmed by obtaining a high antibody titre after a booster dose between 6 and 18 months after primary vaccination. Antibodies against HAV are predicted to persist for many years (at least 10).
Contraindications:
Hypersensitivity to any of the components of the vaccine. Vaccination should be postponed in the event of a serious illness with fever.
Precautions:
People who develop symptoms suggestive of hypersensitivity after the administration of the vaccine should not receive the Next dose. Before vaccination of people who come from epidemiologically threatened areas and probably have previously undergone HAV infection and / or history of jaundice, consideration should be given to testing for antibodies to hepatitis A
Pregnancy and lactation:
Safety in pregnancy - cat. C. The vaccine should not be given to pregnant women unless there is a high risk of HAV infection and the benefits of administering the vaccine justify the potential risk to the fetus. Caution should be exercised when administering a breastfeeding vaccine.
Side effects:
Very common (> 1/10): local reactions at the injection site (usually mild and transient): pain, tenderness, increased warmth of the skin, edema, erythema; headache (in adults). Common (> 1/100, <1/10): local reactions at the injection site (strokes, pain); general symptoms (weakness, fatigue, fever, abdominal pain); diarrhea, vomiting; muscle pain, shoulder pain, low back pain; headache (in children and adolescents). Rare (> 1/1000, <1/100): muscle stiffness, pruritus, skin rash, urticaria. Very rare (<1 / 10,000): increase in liver enzymes. There have been isolated cases of effects on the nervous system (including Guillain-Barre syndrome) and immune-mediated diseases such as thrombocytopenia. There is a risk of an anaphylactic reaction (the patient should be observed at least 30 min after vaccination).
Dosage:
Intramuscularly in the deltoid muscle. In people with bleeding disorders (eg patients with haemophilia), the vaccine may be given intramuscularly with remedial measures; exceptionally, in these people the vaccine can be given subcutaneously. Vaccination consists of one primary dose and one supplementary dose given according to the schedule. The original dose at the selected date: children and adolescents from age 2 to 17 years inclusive - 1 dose 0.5 ml (25 U); adults from 18 years - 1 dose 1 ml (50 U). Supplementary dose between 6 and 18 months after the initial dose: children and adolescents from 2 to 17 years of age - 0.5 ml (25 U); adults - 1 ml (50 U). The vaccine may be given as a booster dose between 6 and 12 months after primary vaccination with another inactivated WZW A vaccine.HIV-infected adults should receive 1 dose of 1 ml (50 U) within the prescribed period, followed by a booster dose, also 1 ml (50 U), 6 months after the initial dose.
(C)
